Skip to content

Application of Esketamine in Anesthesia of Autism Children

Application of Esketamine in Anesthesia of Autism Children Undergoing Colonic Transendoscopic Enteral Tubing

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05960942
Enrollment
120
Registered
2023-07-27
Start date
2023-08-01
Completion date
2023-10-30
Last updated
2023-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Keywords

fecal Microbiota Transplantation, transendoscopic enteral tube, Gut microbiota, anaesthesia

Brief summary

Autism Spectrum Disorder (ASD) is a group of serious neurodevelopmental disorders. Autistic children appear with significant frequency for medical services, lots of which requiring procedural sedation or anaesthesia. Autistic children have often been described as difficult to sedate or anesthetize due to a variety of ASD symptoms. It is a challenging task to provide safe and effective sedation during the procedure of colonic TET for FMT in autism children. The investigators intend to explore an optimum anesthetic regimen for autism children undergoing endoscopic procedures.

Detailed description

Autistic children appear with significant frequency for medical services, lots of which requiring procedural sedation or anaesthesia. The participants have often been described as difficult to sedate or anesthetize due to a variety of ASD symptoms. It is a challenging task to provide safe and effective sedation during the procedure of colonic TET for FMT in autism children. The primary objective was to compare the clinical efficacy and safety of propofol-esketamine (PE) with propofol-sufentanil (PS) for deep sedation in the procedure of colonic TET in ASD children. A secondary objective was to compare adverse events (AEs) and recovery in those children during/after either PE or PS sedation.

Interventions

DRUGpropofol combined with esketamine

In group PE, esketamine was firstly administered at a dose of 0.3 mg.kg-1, followed immediately by propofol with a single intravenous dose of 2.0 mg.kg-1.

DRUGpropofol-sufentanil

In group PS, sufentanil was administered intravenously at a dose of 0.2 μg.kg-1, then 2.0 mg.kg-1 propofol was intravenously injected.

Sponsors

Nanjing Medical University
CollaboratorOTHER
The Second Hospital of Nanjing Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Years to 14 Years
Healthy volunteers
No

Inclusion criteria

* (1) aged 2-12 years; * (2) diagnosed with ASD by pediatric psychiatrists in accordance with the criteria in the Fifth Edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-V); * (3) evaluated as American Society of Anesthesiologists (ASA) physical status I-II; * (4) scheduled for colonic TET procedure.

Exclusion criteria

* (1) oral sedation (premedication) before intravenous catheter placement; * (2) any contraindication to study medications; * (3) other circumstances in which the investigator determined that a patient was not suitable for participation in the clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
movement score during the procedurethrough study completion, an average of 10 minutes(1 = no movement; 2 = semipurposeful allowing continuation of the procedure; 3 = vigorous purposeful movements withholding the procedure)
first movement timeUp to 1 hour after the procedurethe time from arriving Postanesthesia care unit to first gross limb movement after procedure

Secondary

MeasureTime frameDescription
degree of emergence agitationUp to 2 hour after the procedure1 = calm; 2 = not calm but could be easily calmed; 3 = not easily calmed, moderately agitated or restless; and 4 = combative, excited, or disoriented, trashing around
time to full recoveryUp to 3 hour after the procedureachieve modified Aldrete score of 10 with the vital signs being normal and stable
arterial blood pressurethrough study completion, an average of 15 minutesarterial blood pressure was measured noninvasively
adverse eventUp to 24 hour after the procedure(including hypoxia (SpO2 \<93% for \>10 seconds) or respiratory depression (apnea \>15 seconds), hypotension (mean arterial pressure \< 20% from baseline) or bradycardia (heart rate \< 60 /min and/or decrease in heart rate \> 20% from baseline) were recorded.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026